Panel A shows whole-cell current traces for Rat-GluA2 with and without CNQX application. Panel B shows whole-cell current traces for Rat-GluA2 plus Hom-TARP-gamma2, before and after CNQX application. Panel C shows magnified Sac-GluA AMPAR traces with TARP-XP 006822518 or TARP-XP 006816113. Panel D shows current traces for Lin-g8707 plus Lin-g16613 with NBQX, CNQX, and DNQX applications. Panel E shows current traces for Lin-g8707 plus Lin-g16613 plus TARP-Lin-g12410 with NBQX, CNQX, and DNQX applications. Panel F shows current traces for Hof-98007595 plus Hof-98019615 with NBQX, CNQX, and DNQX applications. Panel G shows current traces for Hof-98007595 plus Hof-98019615 plus TARP-Hof-98036255 with CNQX, DNQX, and NBQX applications.
Effects of quinoxalinediones on diverse AMPARs. (A– G ) Example recordings from oocytes expressing indicated AMPARs and TARPs. Quinoxalinediones CNQX, DNQX, and NBQX (each at 100 µM) were used in two protocols: glutamate (1 mM) was pre-applied, and during glutamate application the quinoxalinedione was co-applied (e.g., A, left); or quinoxalinedione was pre-applied, and then glutamate was co-applied (e.g., A, right). Note how the quinoxalinedione-mediated decreases in glutamate-gated current amplitude (A–F) or quinoxalinedione-mediated increases in glutamate-gated current amplitude (C) are similar in either protocol. Insets in B–F show magnified views of the same recordings to illustrate currents gated by quinoxalinediones in some receptors (note different scale bars).